<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610125</url>
  </required_header>
  <id_info>
    <org_study_id>Children CAR-T</org_study_id>
    <nct_id>NCT04610125</nct_id>
  </id_info>
  <brief_title>Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children</brief_title>
  <official_title>Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of&#xD;
      Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and&#xD;
      Lymphoid Tissue Tumors in Children&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single car consists of scFv, hinge region, transmembrane region, costimulatory domain and&#xD;
      zeta subunit of CD3.Prior to CAR-T cell infusion, the patients will be subjected to&#xD;
      preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for&#xD;
      adverse reactions and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">June 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within first one month after CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>Remission Rate including complete remission(CR)、partial response(PR)、No remission(NR)、progressive disease(PD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Auto CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Auto CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Auto CAR-T</intervention_name>
    <description>Biological: Auto CAR-T</description>
    <arm_group_label>Auto CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide,Fludarabine</intervention_name>
    <description>Drug: Cyclophosphamide,Fludarabine</description>
    <arm_group_label>Auto CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Leukapheresis</description>
    <arm_group_label>Auto CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent and be willing and able to comply with the visit, treatment&#xD;
             regimen, laboratory examination and other requirements of the study as stipulated in&#xD;
             the trial flow chart;&#xD;
&#xD;
          2. Patients with relapsed and refractory hematopoiesis and lymphoid tissue tumors&#xD;
             confirmed by clinical diagnosis;&#xD;
&#xD;
          3. Age: 1-18 years (including boundary value), both male and female;&#xD;
&#xD;
          4. Subjects with Lansky score ≥ 50;&#xD;
&#xD;
          5. The results of treatment-related antigens were positive;&#xD;
&#xD;
          6. The expected survival time is more than 3 months from the date of signing the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe cardiac insufficiency and left ventricular ejection fraction &lt; 50%;&#xD;
&#xD;
          2. He had a history of severe lung function damage;&#xD;
&#xD;
          3. Combined with other advanced malignant tumors;&#xD;
&#xD;
          4. Severe infection was found and could not be effectively controlled;&#xD;
&#xD;
          5. With metabolic diseases (except diabetes mellitus);&#xD;
&#xD;
          6. Combined with severe autoimmune disease or congenital immunodeficiency;&#xD;
&#xD;
          7. Untreated active hepatitis (hepatitis B, defined as positive HBsAg, HBV-DNA ≥ 500 IU /&#xD;
             ml and abnormal liver function; hepatitis C, defined as hepatitis C antibody [HCV AB]&#xD;
             positive, HCV-RNA higher than the detection limit of the analysis method and abnormal&#xD;
             liver function) or combined with hepatitis B and hepatitis C co infection;&#xD;
&#xD;
          8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency&#xD;
             syndrome (AIDS), or syphilis infection;&#xD;
&#xD;
          9. Severe allergy history of biological products (including antibiotics);&#xD;
&#xD;
         10. Patients with acute graft-versus-host reaction (GVHD) after one month of&#xD;
             discontinuation of immunosuppressants were still present;&#xD;
&#xD;
         11. The presence of other serious physical or mental illness or laboratory abnormalities&#xD;
             that may increase the risk of participating in the study, or interfere with the&#xD;
             results of the study, and patients considered unsuitable for the study by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lian Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianqiang Li, PhD&amp;MD</last_name>
    <phone>008615511369555</phone>
    <email>limmune@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric hematology, Hebei Medical University Fourth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian Jiang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lian Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianqiang Li, PhD &amp; MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

